A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33579791.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0140 and PMC identifier 11305113.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drugs that target Bruton tyrosine kinase (BTK) have been highly successful and changed the landscape of therapies in B-cell lymphomas. However, their lower rates of effectiveness in follicular lymphoma are unexplained. Recent work describes inactivating BTK mutations that show that at least some follicular lymphomas do not require BTK.<i>See related article by Hu et al., p. 2301</i>.
Medical subject headings
- Lymphoma, B-Cell
- Lymphoma, Follicular